

Supplementary Table 1. Aquaporin-4 (AQP4) IgG and myelin oligodendrocyte glycoprotein (MOG) IgG status in our cohort.

Total number	111
N (%) tested for serum AQP4-IgG	106 (95.5%)
N (%) serum AQP4-IgG positive	77 (69.4%)
N (%) serum AQP4-IgG negative	29 (26.4%)
N (%) tested for CSF AQP4-IgG	30 (27.3%)
N (%) CSF AQP4-IgG positive	16 (14.5%)
N (%) CSF AQP4-IgG negative	14 (12.7%)
Total N (%) tested for AQP4-IgG (serum and/or CSF)	108 (97.3%)
Total N (%) AQP4-IgG positive (serum and/or CSF)	80 (72.0%)
Total N (%) AQP4-IgG negative (serum and/or CSF)	28 (25.2%)
N (%) tested for serum MOG-IgG	17 (15.3%)
N (%) serum MOG-IgG positive	5 (4.5%) - excluded
N (%) double seropositive	0 (0%)
N (%) double seronegative	8 (7.3%)
N (%) not tested for either Ab	3 (2.7%)
N (%) AQP4-IgG (serum and/or CSF) negative with unknown MOG status in the whole cohort	15 (13.5% of the whole cohort, 14.2% of the included cohort)